The anti-tumour effects of the prodrugs N-l-leucyl-doxorubicin and vinblastine-isoleucinate in human ovarian cancer xenografts
Open Access
- 1 December 1992
- journal article
- research article
- Published by Springer Nature in British Journal of Cancer
- Vol. 66 (6) , 1044-1047
- https://doi.org/10.1038/bjc.1992.407
Abstract
No abstract availableKeywords
This publication has 16 references indexed in Scilit:
- Comparative antitumour activity of vinblastine-isoleucinate and related vinca alkaloids in human tumour xenograftsEuropean Journal Of Cancer, 1992
- Phase I study of vintriptol, a tryptophan ester of vinblastineEuropean Journal of Cancer and Clinical Oncology, 1991
- Doxorubicin compared with related compounds in a nude mouse model for human ovarian cancerEuropean Journal of Cancer and Clinical Oncology, 1990
- Prodrugs.British Journal of Clinical Pharmacology, 1989
- Immunodetection of cathepsins b and l present in and secreted from human pre‐malignant and malignant colorectal tumour cell linesInternational Journal of Cancer, 1989
- Preclinical phase II studies in human tumor lines: A European multicenter studyEuropean Journal of Cancer and Clinical Oncology, 1988
- Secondary screening of platinum compounds in human ovarian cancer xenografts in nude miceEuropean Journal of Cancer and Clinical Oncology, 1985
- Vinblastin-23-oyl amino acid derivatives: chemistry, physicochemical data, toxicity, and antitumor activities against P388 and L1210 leukemiasJournal of Medicinal Chemistry, 1985
- Amino acid and dipeptide derivatives of daunorubicin. 1. Synthesis, physicochemical properties, and lysosomal digestionJournal of Medicinal Chemistry, 1980
- Amino acid and dipeptide derivatives of daunorubicin. 2. Cellular pharmacology and antitumor activity of L1210 leukemic cells in vitro and in vivoJournal of Medicinal Chemistry, 1980